BTK inhibitor therapy for chronic lymphocytic leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how well a type of targeted therapy called a BTK inhibitor works for people with chronic lymphocytic leukemia (CLL), a cancer of the blood and bone marrow. It includes both people who have never been treated and those whose cancer came back or didn't get better. The goal is to understand real-world outcomes and help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with chronic lymphocytic leukemia (CLL) and need treatment.
- You either have not received treatment before, or your CLL has come back or not responded to earlier treatment.
- You have taken or are taking a BTK inhibitor for at least 3 months.
- You have had at least one follow-up visit during your BTK inhibitor treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies an investigational drug called epcoritamab, given after your usual treatment (a BTK inhibitor), to see if it can clear remaining CLL cells and reduce the chance of the cancer coming back. It's for people with CLL that has high-risk features, like genetic changes or resistance to prior treatments.
This trial tests a new approach for people newly diagnosed with high-risk CLL or SLL. It combines your own immune cells (CAR-T cells) with a targeted pill (BTK inhibitor) to try to attack the cancer more effectively. It may be an option if you have certain high-risk genetic features and haven't had prior chemotherapy.
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
This study compares two oral targeted therapies, rocbrutinib and pirtobrutinib, for people with CLL or SLL whose disease has come back or stopped responding after treatment with a covalent BTK inhibitor (like ibrutinib). The goal is to see which drug works better and has fewer side effects.
This study looks at what happens to patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after they stop taking a type of targeted therapy called a BTK inhibitor. It aims to understand treatment patterns and outcomes to help guide future care.
This study looks at CLL patients who are taking or may take a BTK degrader (a newer type of targeted therapy) to find out what factors influence how well the treatment works. It aims to help doctors understand who benefits most from this approach.
Hear when a new CLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.